“Extending that logic out to 1.2B doses per year

“Extending that logic out to 1.2B doses per year, and using a conservative profit margin of $100/dose, that equates to ~$120B of Net Income per year -- for as many years as leronlimab might be needed.”

IMO, these are unrealistic calculations. There have been only 3 million confirmed cases worldwide and no doubt tens of millions of unconfirmed cases, but only 250K + deaths (500K+ hospitilizations?). From these numbers we can clearly see that not everyone needs leronlimab to treat COVID19 (not even close to 1.2 billion doses per year). Also, they’ll eventually be a vaccine which will reduce demand for leronlimab as a treatment.

Now, could leronlimab be used to patients who are hospitalized for the flu? Sure, but testing will need to be collected first. Could leronlimab become the standard for HIV mono therapy, combo and prep? Sure, but the mono and prep trial need to get stated. Could leronlimab treat multiple cancers worldwide? Sure, but those trials need to get going. My point is that there are many indications that can bring in revenues for CYDY but I wouldn’t count on $120 billion of net revenue per year for this year, or any year, for COVID.